Univariate analysis of factors affecting OS
| Univariate . | P . | HR (95% CI) . |
|---|---|---|
| Sex (female) | .067 | 0.726 (0.515-1.02) |
| Age | <.0001 | 1.033 (1.016-1.051) |
| iFLC∗ | .009 | 1.484 (1.111-1.981) |
| dFLC∗ | .029 | 1.321 (1.028-1.697) |
| NTProBNP∗ | <.0001 | 1.87 (1.447-2.416) |
| Creatinine∗ | <.0001 | 3.294 (1.852-5.858) |
| Bilirubin | .267 | 1.353 (0.793-2.309) |
| ALP | .861 | 0.948 (0.522-1.721) |
| Mayo 2004 staging with European modification | ||
| Stage 1 | Ref | |
| Stage 2 | .378 | 1.274 (0.744-2.18) |
| Stage 3a | <.0001 | 2.522 (1.529-4.161) |
| Stage 3b | .001 | 2.916 (1.533-5.545) |
| Mayo 2012 staging | ||
| Stage 1 | Ref | |
| Stage 2 | .194 | 1.592 (0.789-3.211) |
| Stage 3 | <.0001 | 3.646 (1.892-7.028) |
| Stage 4 | <.0001 | 3.654 (1.895-7.045) |
| Organ involvement | ||
| Cardiac | .011 | 1.575 (1.112-2.23) |
| Renal | .352 | 1.188 (0.826-1.708) |
| Liver | .753 | 0.925 ( 0.57-1.502) |
| Hematologic response at 12 mo | ||
| CR | Ref | |
| VGPR | .001 | 2.343 (1.409-3.895) |
| PR | <.0001 | 3.692 (2.196-6.208) |
| NR | <.0001 | 4.219 (1.932-9.213) |
| FLC-MS status, FLC-MS positive vs FLC-MS negative | <.0001 | 3.098 (1.752-5.478 |
| Combined hematologic response and FLC-MS status | ||
| 12-mo CR and FLC-MS negative | Ref | |
| 12-mo CR and FLC-MS positive | .019 | 3.37 (1.146-9.915) |
| 12-mo VGPR and FLC-MS negative | .015 | 4.801 (1.353-17.041) |
| 12-mo VGPR and FLC-MS positive | .002 | 6.054 (2.171-16.883) |
| 12-mo PR/NR | <.0001 | 10.15 (3.710-27.766) |
| Further response | ||
| 12-mo iFLC >20 mg/L vs <20 mg/L | <.0001 | 3.035 (1.845-4.992) |
| 12-mo dFLC >10 mg/L vs <10 mg/L | <.0001 | 2.108 (1.454-3.05) |
| Univariate . | P . | HR (95% CI) . |
|---|---|---|
| Sex (female) | .067 | 0.726 (0.515-1.02) |
| Age | <.0001 | 1.033 (1.016-1.051) |
| iFLC∗ | .009 | 1.484 (1.111-1.981) |
| dFLC∗ | .029 | 1.321 (1.028-1.697) |
| NTProBNP∗ | <.0001 | 1.87 (1.447-2.416) |
| Creatinine∗ | <.0001 | 3.294 (1.852-5.858) |
| Bilirubin | .267 | 1.353 (0.793-2.309) |
| ALP | .861 | 0.948 (0.522-1.721) |
| Mayo 2004 staging with European modification | ||
| Stage 1 | Ref | |
| Stage 2 | .378 | 1.274 (0.744-2.18) |
| Stage 3a | <.0001 | 2.522 (1.529-4.161) |
| Stage 3b | .001 | 2.916 (1.533-5.545) |
| Mayo 2012 staging | ||
| Stage 1 | Ref | |
| Stage 2 | .194 | 1.592 (0.789-3.211) |
| Stage 3 | <.0001 | 3.646 (1.892-7.028) |
| Stage 4 | <.0001 | 3.654 (1.895-7.045) |
| Organ involvement | ||
| Cardiac | .011 | 1.575 (1.112-2.23) |
| Renal | .352 | 1.188 (0.826-1.708) |
| Liver | .753 | 0.925 ( 0.57-1.502) |
| Hematologic response at 12 mo | ||
| CR | Ref | |
| VGPR | .001 | 2.343 (1.409-3.895) |
| PR | <.0001 | 3.692 (2.196-6.208) |
| NR | <.0001 | 4.219 (1.932-9.213) |
| FLC-MS status, FLC-MS positive vs FLC-MS negative | <.0001 | 3.098 (1.752-5.478 |
| Combined hematologic response and FLC-MS status | ||
| 12-mo CR and FLC-MS negative | Ref | |
| 12-mo CR and FLC-MS positive | .019 | 3.37 (1.146-9.915) |
| 12-mo VGPR and FLC-MS negative | .015 | 4.801 (1.353-17.041) |
| 12-mo VGPR and FLC-MS positive | .002 | 6.054 (2.171-16.883) |
| 12-mo PR/NR | <.0001 | 10.15 (3.710-27.766) |
| Further response | ||
| 12-mo iFLC >20 mg/L vs <20 mg/L | <.0001 | 3.035 (1.845-4.992) |
| 12-mo dFLC >10 mg/L vs <10 mg/L | <.0001 | 2.108 (1.454-3.05) |
iFLC, involved free light chain; ALP, alkaline phosphatase; 95% CI, confidence interval; mo, month; NTProBNP, N-terminal probrain natriuretic peptide; Ref, reference.